GO:0045517 interleukin-20 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045517 (interleukin-20 receptor binding) is a molecular function defined as binding to an interleukin-20 receptor [QuickGO].
• The interleukin-20 receptor system is shared by several IL-10 family cytokines, including IL-20, IL-24, and IL-26, which engage receptor complexes containing IL-20RA and IL-20RB [2, 3, 7].
• Structural studies show that IL-20R2 (IL-20RB) is a shared receptor subunit that binds cytokines such as IL-20 and IL-24, providing a basis for receptor sharing and activation.
• IL-20 receptor binding is implicated in cancer biology, including colorectal cancer and breast cancer, where receptor expression and cytokine activity influence tumor cell behavior [1, 4].
• The IL-20 receptor complex is also relevant to other diseases, such as glaucoma, where IL-20RA has been implicated in pathogenesis.
• Experimental approaches to study this function include knockout, knock-in, and overexpression models, as well as binding assays and structural analysis [2, 3, 4].
Description
Interleukin-20 receptor binding (GO:0045517) is a molecular function that describes the interaction between a ligand and an interleukin-20 receptor. This term captures the binding event that initiates signaling through receptor complexes containing IL-20RA and IL-20RB, which are shared by several cytokines of the IL-10 family [2, 3, 7]. The function is central to understanding how cytokines such as IL-20, IL-24, and IL-26 transmit signals into cells and how these signals contribute to physiology and disease [3, 4, 7]. Researchers study this term to dissect cytokine-receptor specificity, to map signaling pathways, and to identify therapeutic targets in cancer and other conditions [1, 2, 4]. Because the same receptor subunits can be used by multiple cytokines, the binding event is a key point of regulation and crosstalk [2, 5].
interleukin-20 receptor binding At A Glance
| GO ID | GO:0045517 |
|---|---|
| GO term | interleukin-20 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-20, interleukin-20 receptor ligand |
| Definition | Binding to an interleukin-20 receptor. |
| Major function | Mediates cytokine-receptor interaction for IL-20 family cytokines |
| Related cytokines | IL-20, IL-24, IL-26 |
| Related receptors | IL-20RA, IL-20RB (IL-20R2) |
What Is GO:0045517?
According to the Gene Ontology, GO:0045517 is defined as binding to an interleukin-20 receptor. In other words, it is the molecular function of a ligand (such as a cytokine) physically interacting with a receptor for interleukin-20. This binding event is the first step in receptor activation and can lead to downstream signaling. The term is used to annotate gene products that exhibit this binding activity, including cytokines and receptor subunits that participate in the interaction [QuickGO].
Why Is interleukin-20 receptor binding Important in Cell Biology?
Interleukin-20 receptor binding is important because it governs the initial step of signaling for several IL-10 family cytokines, which are involved in immune regulation, tissue homeostasis, and cancer [2, 3, 7]. Dysregulation of this binding can alter cell proliferation, survival, and inflammatory responses, contributing to diseases such as colorectal cancer and breast cancer [1, 4]. Understanding the molecular details of this interaction helps researchers design targeted therapies and interpret disease-associated changes in receptor expression [1, 2, 8].
• Defines the first step in IL-20 family cytokine signaling [2, 3].
• Explains receptor sharing among IL-20, IL-24, and IL-26 [2, 3, 7].
• Relevant to cancer biology, including colorectal and breast cancer [1, 4].
• Provides a target for therapeutic intervention in cytokine-driven diseases [4, 6].
• Helps interpret receptor expression data in patient samples.
• Links structural biology to functional outcomes [2, 5].
• Involved in immune and epithelial cell communication [3, 7].
• Associated with glaucoma pathogenesis through IL-20RA.
• Guides experimental design for binding and signaling assays [2, 3].
• Supports development of cytokine-based immunotherapies.
Molecular Mechanism of interleukin-20 receptor binding
Cytokine recognition and receptor sharing
In simple terms: Different cytokines can use the same receptor parts to send signals.
Interleukin-20 receptor binding involves cytokines such as IL-20, IL-24, and IL-26 interacting with receptor complexes that include IL-20RA and IL-20RB. Structural studies show that IL-20R2 (IL-20RB) is a shared subunit that binds cytokines like IL-20 and IL-24, enabling receptor sharing and activation. IL-26 also targets cells through IL-20RA and IL-10RB, illustrating the combinatorial use of receptor chains. This sharing means that binding specificity is determined by the combination of cytokine and receptor subunits present on the cell surface [2, 5].
Structural basis of binding
In simple terms: The shape of the cytokine and receptor determines how tightly they stick together.
Molecular modeling and structural analyses have provided insights into how IL-19 and related cytokines recognize their receptors, revealing novel aspects of receptor recognition within the IL-10 family. The crystal structure of IL-20R2 in complex with cytokines has elucidated the basis for receptor sharing and activation, highlighting key contact residues and conformational changes. These studies help explain how binding affinity and specificity are achieved and how mutations might affect interaction [2, 5].
Receptor complex assembly and activation
In simple terms: Once the cytokine binds, receptor chains come together to start a signal.
Binding of IL-20 or IL-24 to IL-20RA and IL-20RB leads to assembly of a functional receptor complex that can activate downstream signaling pathways [2, 7]. IL-24, also known as MDA-7, kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10, indicating that receptor binding is a critical determinant of biological outcome. The assembly process often involves sequential binding events and may be influenced by the presence of other receptor chains such as IL-10RB [3, 7].
Regulation and antagonism
In simple terms: Other molecules can block or fine-tune the binding process.
IL-10 can antagonize IL-24 activity at the IL-20 receptor, suggesting that competitive binding or receptor modulation regulates signaling. The expression levels of receptor subunits can also affect binding capacity and cellular responses [1, 8]. Understanding these regulatory mechanisms is important for interpreting experimental results and for designing interventions that target the binding interface [4, 6].
Key Genes Involved in GO:0045517 interleukin-20 receptor binding
The following genes and proteins are directly involved in or closely related to interleukin-20 receptor binding, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL20 | Cytokine ligand that binds IL-20 receptor | Studied for its role in inflammation and cancer [2, 7] |
| IL20RA | Receptor subunit for IL-20 family cytokines | Implicated in colorectal cancer and glaucoma [1, 8] |
| IL20RB | Shared receptor subunit (IL-20R2) | Structural basis for receptor sharing |
| IL24 | Cytokine (MDA-7) that binds IL-20 receptor | Kills breast cancer cells; antagonized by IL-10 [4, 6] |
| IL26 | Cytokine that targets cells via IL-20RA and IL-10RB | T-cell lymphokine affecting epithelial cells |
| IL10 | Antagonizes IL-24 at the IL-20 receptor | Modulates IL-24 activity |
| IL19 | IL-10 family cytokine with modeled receptor complex | Molecular modeling of receptor recognition |
| IL10RB | Receptor chain used by IL-26 | Part of IL-26 receptor complex |
| JAK1 | Kinase downstream of cytokine receptors | Potential signaling mediator (generic) |
| STAT3 | Transcription factor activated by IL-10 family cytokines | Downstream effector (generic) |
| STAT1 | Transcription factor involved in cytokine signaling | Downstream effector (generic) |
| SOCS3 | Negative regulator of cytokine signaling | Potential feedback regulator (generic) |
| IL22 | IL-10 family cytokine | Related family member (generic) |
| IL28A | IL-10 family cytokine | Related family member (generic) |
| IL29 | IL-10 family cytokine | Related family member (generic) |
| IL20RA/IL20RB complex | Functional receptor for IL-20 | Target for binding studies [2, 7] |
How Is interleukin-20 receptor binding Regulated?
The binding of interleukin-20 to its receptor can be regulated at multiple levels. Receptor expression levels, as seen in colorectal cancer, influence the capacity for binding and downstream signaling. Antagonism by IL-10 provides an example of competitive regulation at the receptor. Additionally, the sharing of receptor subunits among multiple cytokines creates opportunities for crosstalk and competition, which can modulate the effective binding of IL-20 [2, 3]. Post-translational modifications and trafficking of receptors may also affect binding, though specific mechanisms are not fully detailed in the cited literature.
interleukin-20 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL20RA | Colorectal cancer | Knockout or overexpression in colorectal cancer cell lines |
| IL24 | Breast cancer | Overexpression and receptor binding assays in breast cancer cells |
| IL20RA | Glaucoma | Knockout or knock-in models in relevant ocular cells |
| IL20RB | Receptor sharing in cancer | Structural and binding studies using purified proteins |
| IL26 | Epithelial cell targeting | Knockout of receptor chains in epithelial cell lines |
Colorectal cancer
Interleukin 20 receptor A expression has been examined in colorectal cancer, and its clinical significance suggests that receptor binding and signaling may contribute to tumor biology. Altered expression of IL20RA could affect the response to IL-20 family cytokines and influence disease progression.
Breast cancer
Human interleukin 24 (MDA-7/IL-24) kills breast cancer cells via the IL-20 receptor, and this activity is antagonized by IL-10. This highlights the IL-20 receptor as a mediator of cytokine-induced cell death and a potential target for immunotherapy [4, 6].
Glaucoma
Research progress on human genes involved in the pathogenesis of glaucoma has implicated IL-20RA among genes of interest, suggesting a role for interleukin-20 receptor binding in this ocular disease.
From interleukin-20 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL20RA mediate IL-20 binding in cancer cells? | IL20RA knockout cell line |
| What is the structural basis of IL-20R2 binding? | Recombinant protein and crystallography |
| Can IL-24 induce cell death via IL-20 receptor? | IL24 overexpression in breast cancer cells |
| Does IL-26 signal through IL-20RA/IL-10RB? | Knockout of IL20RA or IL10RB in epithelial cells |
| Is IL-20RA involved in glaucoma? | Knock-in or knockout animal models |
| How does IL-10 antagonize IL-24? | Competitive binding assays with IL-10 |
How to Study the interleukin-20 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Cytokine-receptor interaction |
| X-ray crystallography | Three-dimensional structure | Receptor sharing mechanism |
| Molecular modeling | Predicted receptor complex | IL-19 receptor recognition |
| Cell viability assay | Cytokine-induced cell death | IL-24 activity in breast cancer |
| Western blot | Phosphorylation of signaling proteins | Downstream activation |
| qPCR | Receptor mRNA expression | Clinical sample analysis |
| Immunohistochemistry | Protein expression in tissues | Colorectal cancer studies |
| RNA-seq | Global gene expression | Pathogenesis research |
Binding assays
Direct binding assays, such as surface plasmon resonance or ELISA, can measure the interaction between IL-20 family cytokines and their receptors. These methods help quantify affinity and specificity, as demonstrated in structural and functional studies [2, 3].
Structural biology
X-ray crystallography and molecular modeling provide atomic-level details of the cytokine-receptor interface. The structure of IL-20R2 with cytokines elucidated receptor sharing, and modeling of the IL-19 receptor complex revealed novel recognition aspects.
Cell-based signaling assays
Reporter assays and phosphorylation analysis can measure downstream signaling after receptor binding. For example, IL-24-induced killing of breast cancer cells via the IL-20 receptor can be assessed using viability assays. IL-26 targeting of epithelial cells can be studied by monitoring STAT activation.
Expression analysis
Quantitative PCR, immunohistochemistry, and RNA-seq can measure receptor expression levels in tissues and cell lines. IL20RA expression in colorectal cancer has been evaluated for clinical significance, and gene expression studies in glaucoma have highlighted IL20RA.
How CRISPR Can Be Used to Study GO:0045517 interleukin-20 receptor binding
Knockout
CRISPR knockout of IL20RA or IL20RB can abolish interleukin-20 receptor binding and downstream signaling, allowing researchers to test the requirement for these receptors in cellular responses. Such models are useful for validating receptor function in cancer cell lines and other systems [1, 2].
Point Mutation
Introducing point mutations in the binding interface of IL-20 or its receptors can help map critical residues for interaction. This approach is informed by structural studies that identify key contact sites [2, 5].
Knock-in
Knock-in of tagged or fluorescently labeled receptors can enable visualization and tracking of receptor complexes in live cells. This can be combined with binding assays to study dynamics [2, 3].
Overexpression
Overexpression of IL-20 family cytokines or their receptors can enhance binding and amplify signaling, facilitating studies of downstream effects such as cell death or proliferation. For example, IL-24 overexpression has been used to study breast cancer cell killing via the IL-20 receptor.
How EDITGENE Supports interleukin-20 receptor binding Research
Researchers studying interleukin-20 receptor binding-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for interleukin-20 receptor binding research.
Frequently Asked Questions About interleukin-20 receptor binding
What is GO:0045517?
GO:0045517 is the Gene Ontology molecular function term for interleukin-20 receptor binding, defined as binding to an interleukin-20 receptor [QuickGO].
What genes are involved in interleukin-20 receptor binding?
Key genes include IL20, IL20RA, IL20RB, IL24, and IL26, which encode cytokines and receptor subunits that participate in the interaction [2, 3, 4].
Which cytokines bind to the interleukin-20 receptor?
IL-20, IL-24, and IL-26 are known to bind receptor complexes containing IL-20RA and IL-20RB [2, 3, 7].
What is the role of IL-20 receptor binding in cancer?
IL-20 receptor binding can influence cancer cell behavior; for example, IL-24 kills breast cancer cells via the IL-20 receptor, and IL20RA expression has clinical significance in colorectal cancer [1, 4].
How is interleukin-20 receptor binding studied?
Common methods include binding assays, structural biology, cell-based signaling assays, and expression analysis [2, 3, 4].
What is the structure of the IL-20 receptor complex?
The IL-20 receptor complex typically includes IL-20RA and IL-20RB; structural studies have elucidated how IL-20R2 binds cytokines.
Is interleukin-20 receptor binding involved in glaucoma?
Research has implicated IL20RA in the pathogenesis of glaucoma, suggesting a potential role for this binding function.
Can CRISPR be used to study interleukin-20 receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of genes involved in this binding [1, 4].
What diseases are associated with interleukin-20 receptor binding?
Associated diseases include colorectal cancer, breast cancer, and glaucoma [1, 4, 8].
How does IL-10 affect interleukin-20 receptor binding?
IL-10 can antagonize IL-24 activity at the IL-20 receptor, indicating a regulatory interaction.
Conclusion
Interleukin-20 receptor binding (GO:0045517) is a molecular function that initiates signaling for several IL-10 family cytokines, with important implications for cancer and other diseases. Structural and functional studies have revealed the basis for receptor sharing and activation, providing a foundation for therapeutic targeting [2, 3, 4]. Continued research using CRISPR models and binding assays will further clarify the roles of this interaction in health and disease [1, 6, 8].
References
- 1. Liu R et al.. 2021. Interleukin 20 receptor A expression in colorectal cancer and its clinical significance.. PeerJ 9:e12467 PMID: 34820194
- 2. Logsdon NJ et al.. 2012. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines.. Proc Natl Acad Sci U S A 109(31):12704-9 PMID: 22802649
- 3. Hör S et al.. 2004. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains.. J Biol Chem 279(32):33343-51 PMID: 15178681
- 4. Zheng M et al.. 2007. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.. Cancer Immunol Immunother 56(2):205-15 PMID: 16710719
- 5. Preimel D et al.. 2004. Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family.. J Mol Model 10(4):290-6 PMID: 15243778
- 6. Persaud L et al.. 2016. Mechanism of Action and Applications of Interleukin 24 in Immunotherapy.. Int J Mol Sci 17(6) PMID: 27271601
- 7. Wang M et al.. 2005. Interleukin-24 and its receptors.. Immunology 114(2):166-70 PMID: 15667561
- 8. Wang HW et al.. 2018. Research progress on human genes involved in the pathogenesis of glaucoma (Review).. Mol Med Rep 18(1):656-674 PMID: 29845210
